Bristol Myers Squibb's Iberdomide Shows Promise in Improving MRD Negativity in Multiple Myeloma
Bristol Myers Squibb announced that their Phase 3 EXCALIBER-RRMM study showed that combining iberdomide with standard therapies significantly improved minimal residual disease negativity rates in relapsed or refractory multiple myeloma patients, with the trial continuing to evaluate other endpoints.